Business Context and Reporting Period
This Form 8-K Current Report was filed by Minerva Neurosciences, Inc. (Nasdaq: NERV) on September 2, 2021. The report discloses the resignation of a named executive officer and the terms of a subsequent separation and consulting agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation terms.
Material Changes
On September 2, 2021, Dr. Jay B. Saoud tendered his resignation as Senior Vice President, Head of Research and Development, effective September 15, 2021. This departure marks a significant change in the company's senior leadership structure.
Guidance, Outlook, and Management Commentary
The filing details a Transition, Separation, and Consulting Agreement with the following key terms:
- Consulting Period: Dr. Saoud will serve as a consultant from September 15, 2021, through June 30, 2022, subject to earlier termination with 30 days' notice.
- Compensation: Consulting fees are set at $412.50 per hour for the first 20 hours per week and $500.00 per hour for additional hours.
- Benefits: The Company will continue paying COBRA premiums through the end of the Consulting Period.
- Equity Vesting: Unvested stock options will vest in full upon completion of the Consulting Period or early termination by the Company. Performance-based restricted stock units (PRSUs) remain eligible to vest based on milestones, including a specific provision for 50% vesting if FDA acceptance of a new drug application for roluperidone is achieved by the end of the Post-Termination Period.
- Exercise Period: Vested options remain exercisable through December 31, 2022, if the consulting period is completed or terminated by the Company, or for 6 months following termination if initiated by Dr. Saoud.
Investor Verification Checklist
- Verify the impact of Dr. Saoud's departure on the development timeline for roluperidone and other pipeline assets.
- Review the full text of the Transition, Separation, and Consulting Agreement (Exhibit 10.1) for additional covenants or liabilities.
- Confirm the Company's plan for replacing the Head of Research and Development.
- Monitor future filings for any acceleration of equity vesting triggered by a change in control.